NRD
EGRX

Nebula Research & Development’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Nebula Research & Development’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,473
Closed -$181K – 906
2023
Q3 		$181K Buy
11,473
+1,117
+11% +$20.1K 0.1% 416
2023
Q2 		$201K Buy
+10,356
New +$246K 0.15% 272

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Nebula Research & Development's EGRX Position: Q4 2023 in Review

Nebula Research & Development sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 11,473 shares — an estimated $181K sold.

Nebula Research & Development first reported a position in EGRX in Q2 2023 and held it in 2 quarters. The position peaked at $201K in Q2 2023. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

  • Nebula Research & Development reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Nebula Research & Development sold 11,473 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $181K.
  • Nebula Research & Development first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2023 and held it in 2 quarters.
  • Nebula Research & Development's Eagle Pharmaceuticals, Inc. position peaked at $201K in Q2 2023.
  • 104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Nebula Research & Development's 13F filing for Q4 2023, filed 14 Feb 2024.